GlobeNewswire Clinical StudiesOriginal article
OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain
Phase 3urcosimodPositive
AI Analysis
Summary
OKYO Pharma announced the first patient enrollment in the Phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain. This represents a major progression in the clinical development of the investigational therapy.
Clinical Trial Data
Phase
3
Outcome Details
First patients enrolled in Phase 3 NEPTUNE trial
Importance:6/10
Sentiment:
0.60
Phase 3Clinical TrialNeuropathic Corneal PainEye DiseaseTrial Enrollment
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on October 6, 2026 11:00 AM